13 results match your criteria: "the 302nd Hospital of Chinese PLA[Affiliation]"
J Cancer
April 2024
Department of Liver Surgery, Peking Union Medical College Hospital, PUMC and Chinese Academy of Medical Sciences, Dongcheng, Beijing 100730, China.
This study aimed to investigate the safety and efficacy of preoperative targeted immunotherapy followed by surgical resection for hepatocellular carcinoma (HCC) patients with macrovascular invasion. Clinical information of HCC patients with macrovascular invasion was collected from four medical centers. These patients were divided into two cohorts: the upfront surgery group (n=40) and the neoadjuvant group (n=22).
View Article and Find Full Text PDFActa Pharm Sin B
July 2020
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Onco Targets Ther
September 2018
Basic Medicine College, Navy Military Medical University of Chinese PLA, Shanghai 200433, People's Republic of China,
Background: Pregnane X receptor (PXR), which is a member of the nuclear receptor protein family (nuclear receptor subfamily 1 group I member 2 [NR 1I2]), mediates the drug-resistance in the hepatocellular carcinoma (HCC) via enhancing the expression of drug-resistance-related genes which accelerate the clearance of antitumor drugs, eg, sorafenib. However, there are few reports on miRNA targeting PXR participating in the epigenetic regulation of PXR in HCC cells.
Materials And Methods: TargetScan 7.
Pharmacol Res
September 2018
School of Foreign Languages, Shaanxi Normal University, Xi'an, 710062, PR China. Electronic address:
Transcription factor E26 transformation specific sequence 1 (ETS-1) is a primary regulator in the metastasis of human cancer cells, especially hepatocellular carcinoma (HCC) cells; and it would affect the prognosis of HCC patients who received chemotherapies. However, the regulatory role of ETS-1 in the resistance of HCC cells to molecular-targeting agent remains poorly understood. In the present work, we demonstrate that high ETS-1 expression correlates with poor prognosis of advanced HCC patients received Sorafenib treatment.
View Article and Find Full Text PDFGene
November 2018
Center for Clinical Laboratory, The 302nd Hospital of Chinese PLA, Beijing 100039, PR China. Electronic address:
Background: To identify the most suitable genetic model for detecting the risk of breast cancer (BC)/ovarian cancer (OC) in specific populations.
Methods: Databases were searched for related studies published up to October 2017. First, VDR genetic polymorphisms were compared in patients with and without cancer.
Cell Death Dis
July 2018
Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, 110840, China.
Hepatocellular carcinoma (HCC) is one of the greatest life threats for Chinese people, and the prognosis of this malignancy is poor due to the strong chemotherapy resistance in patients. Notch pathway components mediate cell survival and epithelial-mesenchymal transition (EMT), and also participate in the induction of multi-drug resistance (MDR). In the present study, we demonstrated the discovery of a novel inhibitor for Notch activating/cleaving enzyme ADAM-17, named ZLDI-8; it inhibited the cleavage of NOTCH protein, consequently decreased the expression of pro-survival/anti-apoptosis and EMT related proteins.
View Article and Find Full Text PDFBiochim Biophys Acta Gen Subj
April 2018
Center for Clinical Laboratory, The 302nd Hospital of Chinese PLA, Beijing 100039, PR China. Electronic address:
Background: Kinase inhibitor sorafenib is the most widely used drug for advanced HCC clinical treatment nowadays. However, sorafenib administration is only effective for a small portion of HCC patients, and the majority develop sorafenib-resistance during treatment. Thus, it is urgent to discover the endogenous mechanism and identify new pharmaceutical targets of sorafenib-resistance.
View Article and Find Full Text PDFBMC Cancer
November 2017
Research Center for Clinical and Translational Medicine, the 302nd Hospital of Chinese PLA, Beijing, 100039, People's Republic of China.
Background: Patients suffering from advanced stage hepatocellular carcinoma (HCC) often exhibit a poor prognosis or dismal clinical outcomes due to ineffective chemotherapy or a multi-drug resistance (MDR) process. Thus, it is urgent to develop a new chemotherapeutic sensitivity testing system for HCC treatment. The presence study investigated the potential application of a novel chemotherapeutic sensitivity-testing system based on a collagen gel droplet embedded 3D-culture system (CD-DST).
View Article and Find Full Text PDFInt J Nurs Stud
January 2018
Center for Clinical Laboratory, The 302nd Hospital of Chinese PLA, Beijing 100039, PR China. Electronic address:
Background: Primary insomnia is one of the most common issues for adults. However, whether to use music intervention as a non-pharmacological method of treatment, as well as which treatment should be preferred, is still a matter of controversy. Therefore, we aimed to compare and rank music interventions and no-music controls for primary insomnia patients.
View Article and Find Full Text PDFSci Rep
November 2017
Department of Pharmacy, General Hospital of Shenyang Military Area Command, Shenyang, 110840, P.R. China.
Hepatocellular carcinoma (HCC) is not sensitive to radiotherapy and chemotherapy and experiences postoperative relapse extremely easy, which is the major cause of the high mortality rate. The Notch signaling pathway is expected to become a new target for the biological treatment of HCC. We searched databases for studies that evaluated the expression of Notch receptors and/or ligands in human HCC tissue.
View Article and Find Full Text PDFOncotarget
September 2017
Center for Clinical Laboratory, The 302nd Hospital of Chinese PLA, Beijing 100039, P.R. China.
Objective: To identify the association between gastrointestinal carcinomas (GIC) risk and UDP-glucuronosyltransferases (UGTs) 1A7 polymorphisms through a systematic review and network meta-analysis.
Results: Seventeen studies were eligible, which included 7738 patients and 18 analyses. First, it was found that compared with non-cancer participants, UGT1A7*1 were significantly decreased in cancer patient groups, especially in hepatocellular carcinoma, colorectal carcinoma, and Asian population groups; UGT1A7*2 was significantly increased in hepatocellular carcinoma and Asian population groups; and UGT1A7*3 was significantly increased in hepatocellular carcinoma, colorectal carcinoma, Caucasian, and Asian population groups.
Cell Biochem Funct
October 2017
Department of Gastroenterology, Chinese PLA General Hospital, Beijing, China.
The p53 protein plays a critical role in suppression of tumour growth; its regulation is not fully understood. Leukaemia/lymphoma-related factor (LRF) promotes tumour cell growth. This study tests a hypothesis that LRF inhibits p53 expression in colon cancer cells.
View Article and Find Full Text PDFTumour Biol
June 2016
Center of Technical and Service, The 302nd Hospital of Chinese PLA, Beijing, 100039, People's Republic of China.
The microRNA miR-452 has been shown to function as a tumor suppressor. However, the cellular mechanism and potential application of miR-452-mediated cancer suppression remain great unknown. This study aims to identify how miR-452 acts in regulating non-small cell lung cancer (NSCLC) proliferation and metastasis.
View Article and Find Full Text PDF